Ark Therapeutics primes market for likely financing update

Viral product-focused manufacturing services company Ark Therapeutics expects to update the market soon regarding possible financing, an announcement issued by the company on Monday disclosed.

Viral product-focused manufacturing services company Ark Therapeutics expects to update the market soon regarding possible financing, an announcement issued by the company on Monday disclosed.

The group announced that it was actively pursuing a number of options regarding the possible financing of the company and its business, including through an issue of equity on a non pre-emptive basis.

The company stated that there was "no guarantee" that the discussions would be successful yet also stated that it believed it would be in a position to "update the market shortly".

This follows a previous attempt by the group to gauge interest among shareholders over a potential equity fund-raising which it said had showed a level insufficient to justify continuing with the proposal.

Over the past year, the company said it had reduced its cost base, terminated all costly investment in early stage product development and re-structured its business to focus solely upon generating revenue from its viral development and manufacturing services based in Finland.

The group advised its shareholders that "in all likelihood, given the current share price and the expected level of investment being discussed, any equity financing proposal will be materially dilutive and subject to shareholder approval."

It added that the group's directors remained confident Ark has the potential to become a profitable, viral focused, contract development and manufacturing organisation.

In the meantime, and as previously announced, the company continues to explore opportunities to monetise its non-core assets, and is in discussions with a number of interested parties.

Ark Therapeutics has seven active clients and a number of further contracts in late stage negotiations.

Unaudited revenue for 2012 was up 300% to approximately £1.8m compared to 2011.

MF

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

Lab-grown meat: how “moo’s law” will drive innovation
Soft commodities

Lab-grown meat: how “moo’s law” will drive innovation

Jim Mellon and Anthony Chow, co-founders of Aim-listed Agronomics, explain why they believe that “cellular agriculture” will benefit from massive long…
16 Apr 2021
The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Lab-grown meat: the new agricultural revolution
Soft commodities

Lab-grown meat: the new agricultural revolution

Vegan alternatives are taking off, but the future of food technology lies in lab-grown meat – cultivating steaks and burgers from animal cells, says A…
16 Apr 2021